Duchnowska, R; Jarząb, M; Żebracka-Gala, J; Matkowski, R; Kowalczyk, A; Radecka, B; Kowalska, M; Pfeifer, A; Foszczyńska-Kłoda, M; Musolino, A; Czartoryska-Arłukowicz, B; Litwiniuk, M; Surus-Hyla, A; Szabłowska-Siwik, S; Karczmarek-Borowska, B; Dębska-Szmich, S; Głodek-Sutek, B; Sosińska-Mielcarek, K; Chmielowska, E; Kalinka-Warzocha, E; Olszewski, Wp; Patera, J; Żawrocki, A; Pliszka, A; Tyszkiewicz, T; Rusinek, D; Oczko-Wojciechowska, M; Jassem, J; Biernat, W; Polish Brain Metastasis, Consortium, Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer, «CLINICAL BREAST CANCER», 2016, 17, pp. 65 - 75 [articolo]
Negri, Fv; Boggiani, D; Rimanti, A; Musolino, A, FCGR, Cetuximab, and Colorectal Cancer Survival-Letter, «CLINICAL CANCER RESEARCH», 2016, 1, pp. 4958 - 4958 [articolo]
Musolino, A; Naldi, N.; Dieci, M. V.; Zanoni, D.; Rimanti, A.; Boggiani, D.; Sgargi, P.; Generali, D. G.; Piacentini, F.; Ambroggi, M.; Cagossi, K.; Gianni, L.; Sarti, S.; Bisagni, G.; Ardizzoni, Andrea; Conte, P. F.; Guarneri, V., Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer, «PHARMACOGENOMICS JOURNAL», 2016, 16, pp. 472 - 477 [articolo]
Musolino, A; Boggiani, ; D;, Sikokis; A;, Rimanti; A;, Pellegrino; B;, Vattiato; R;, Sgargi; P;, Falcini; F;, Caminiti; C;, Michiara; M;, Leonardi; F,, Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive
breast cancers, «CANCER TREATMENT REVIEWS», 2016, 43, pp. 1 - 7 [articolo]
Pellegrino, ; Bella, ; Michiara, ; Zanelli, ; Naldi, ; Porzio, ; Bortesi, ; Boggiani, ; Zanoni, ; Camisa, ; Neri, ; T., M.; Pinto, ; Musolino, A, Triple negative status and BRCA mutations in contralateral breast cancer: A population-based study, «ACTA BIO-MEDICA DE L'ATENEO PARMENSE», 2016, 6, pp. 54 - 63 [articolo]
Guarneri, V.; Dieci, M. V.; Frassoldati, A.; Maiorana, A.; Ficarra, G.; Bettelli, S.; Tagliafico, E.; Bicciato, S.; Generali, D. G.; Cagossi, K.; Bisagni, G.; Sarti, S.; Musolino, A.; Ellis, C.; Crescenzo, R.; Conte, P., Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer, «THE ONCOLOGIST», 2015, 20, pp. 1001 - 1010 [articolo]
Buti, Sebastiano; Bersanelli, Melissa; Tiseo, Marcello; Ardizzoni, Andrea; Musolino, Antonino, BOLERO-3 results: Pharmacological activity or pharmacokinetic effect?, «THE LANCET ONCOLOGY», 2014, 15, pp. e304 - e304 [articolo]
Negri, F.V; Musolino, A.; Naldi, N.; Bortesi, B.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Chernyschova, N.; Bisagni, G.; Loupakis, F.; Ruzzo, A.; Neri, T.M.; Ardizzoni, A., Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy, «PHARMACOGENOMICS JOURNAL», 2014, 14, pp. 14 - 19 [articolo]
Bisagni, G; Musolino, A.; Panebianco, M.; De Matteis, A.; Nuzzo, F.; Ardizzoni, A.; Gori, S.; Gamucci, T.; Passalacqua, R.; Gnoni, R.; Moretti, G.; Boni, C., The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer, «CANCER CHEMOTHERAPY AND PHARMACOLOGY», 2013, 71, pp. 1051 - 1057 [articolo]
Musolino, Antonino; Michiara, Maria; Conti, Giovanni Maria; Boggiani, Daniela; Zatelli, Marella; Palleschi, Dario; Bella, Maria Angela; Sgargi, Paolo; Di Blasio, Beatrice; Ardizzoni, Andrea, Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study, «JOURNAL OF CLINICAL ONCOLOGY», 2012, 30, pp. 2362 - 2368 [articolo]
Guarneri, V.; Frassoldati, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Sarti, S.; Ravaioli, A.; Cavanna, L.; Giardina, G.; Musolino, A.; Untch, M.; Orlando, L.; Artioli, F.; Boni, C.; Generali, D. G.; Serra, P.; Bagnalasta, M.; Marini, L.; Piacentini, F.; D'Amico, R.; Conte, P., Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study, «JOURNAL OF CLINICAL ONCOLOGY», 2012, 30, pp. 1989 - 1995 [articolo]
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A, Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma, «CANCER», 2011, 117, pp. 964 - 973 [replica/breve intervento]
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A, Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study, «CANCER», 2011, 117, pp. 1837 - 1846 [replica/breve intervento]
Musolino, A; Guazzi, A; Nizzoli, R; Panebianco, M; Mancini, C; Ardizzoni, A, Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma, «TUMORI», 2010, 96, pp. 24 - 27 [articolo]
Boggiani D; Musolino A; Panebianco M; Franciosi V; Vasini G; Salvagni S; Ardizzoni A, ACTIVITY AND SAFETY OF DOSE-ADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DA-POCH-R) IN VERY ELDERLY PATIENTS WITH POOR-PROGNOSTIC UNTREATED DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA, «ANNALS OF ONCOLOGY», 2010, 21, pp. 352 - 352 [abstract]
